Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Study reveals role of KLF14 regulatory gene in type 2 diabetes

A team of researchers, led by King's College London and the University of Oxford, have found that a gene linked to type 2 diabetes and cholesterol levels is in fact a 'master regulator' gene, which controls the behaviour of other genes found within fat in the body.

16 May 2011

Study reveals crucial role of histone deacetylases in type 2 diabetes

A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.

16 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Majority of high-risk heart disease patients have poor adherence to statin treatment

A new study from North Carolina State University shows that the vast majority of patients at high risk for heart disease or stroke do a poor job of taking statins as prescribed. That's especially unfortunate, because the same study shows that taking statins can significantly increase the quality and length of those patients' lives.

13 May 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes.

11 May 2011

Independent investigator begins pump trial of Biodel's two ultra-rapid human insulin formulations

Biodel Inc. announced today that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations of recombinant human insulin.

10 May 2011

A large belly as dangerous as smoking a pack of cigarettes daily

Did you know that a large belly carries a risk equivalent for coronary artery disease comparable to smoking a pack of cigarettes daily or having high cholesterol? People with coronary artery disease and expanded waistlines are at more than twice the risk of dying, including those with a Body Mass Index (BMI) in the normal range.

10 May 2011

Charisela develops breakthrough adiponectin assay

Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it has developed an adiponectin assay with major advantages over existing technologies, including the elimination of dilutions. Adiponectin (Acrp30), an adipocytokine, is important in many therapeutic arenas, including type 2 diabetes, obesity, atherosclerosis, and rheumatoid arthritis.

9 May 2011

Diamyd Medical announces European Phase III study results in type 1 diabetes

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.

9 May 2011

Innovative detection practices may prevent liver diseases

Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.

9 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

Spherix effects 1-for-10 reverse stock split

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation, as amended, to effect a 1-for-10 reverse stock split of its common stock that will become effective at end of business today.

7 May 2011

New project to explore European diet and healthy ageing

People are living longer. Rising living standards, improved lifestyle and better education, as well as greater access to quality healthcare services has meant that we can expect to reach 78 years of age, an increase of six years compared to the 1980s. However, data also shows that Europeans live to just over 60 years without being limited in their day-to-day activities by ill-health or disabilities.

6 May 2011

Structured exercise training can reduce HbA1c levels in patients with diabetes

Implementing structured exercise training, including aerobic, resistance or both, was associated with a greater reduction in hemoglobin A1c levels for patients with diabetes compared to patients in the control group, and longer weekly exercise duration was also associated with a greater decrease in these levels, according to results of an analysis of previous studies, published in the May 4 issue of JAMA.

4 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Diabetes cell implant company approved for Argentina clinical trial

Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.

3 May 2011

Poor sleep may contribute to high insulin resistance in diabetic people

In the largest study of it kind to establish a link between sleep and diabetes, researchers found that people with diabetes who sleep poorly have higher insulin resistance, and a harder time controlling the disease.

3 May 2011